PO.ET02.10 · 实验与分子治疗
Drug Combinations, Repurposing, and Differentiation
-
-
- 4455 4455 肿瘤电场治疗(TTFields)联合标准化疗和PD-L1阻断在小细胞肺癌临床前模型中的疗效 Efficacy of Tumor Treating Fields (TTFields) together with standard chemotherapy and PD-L1 blockage in preclinical models of small cell lung carcinoma Rotem Engelman, Lina Somri-Gannam, Talya Borkum, Roni Blatt, Daria Gerasimova, Shay Cahal, Catherine Tempel Brami, Mai Shai, Yiftah Barsheshet, Eyal Dor-On, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
- 4456 4456 肿瘤电场治疗（TTFields）在非小细胞肺癌模型中增强标准免疫化疗的抗肿瘤和免疫应答 Tumor Treating Fields (TTFields) potentiate antitumor and immune responses to standard immunochemotherapy in non-small cell lung cancer models Boris Brant, Yiftah Barsheshet, Tali Voloshin, Tal Kan, Tharwat Haj Khalil, Simona Zisman-Rozen, Lilach Koren, Avital Vorontsov, Bella Koltun, Cfir David, Anat Klein-Goldberg, Efrat Zemer-Tov, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
-
-
-
-
-
- 4462 4462 奈必洛尔抑制细胞生长、抑制自噬流，并在前列腺癌细胞中与比卡鲁胺联合增强生长抑制作用 Nebivolol inhibits cell growth, inhibits autophagic flux, and enhances growth inhibition in combination with bicalutamide in prostate cancer cells Swarnil Mandal, Chia-Ling Wu, Shivaani S. Kanna, Wangjia Cao, Meghana V. Trivedi
- 4463 4463 将抗痴呆药物美金刚（一种双重alpha7-nAChR NMDAR拮抗剂）重新利用为人鳞状细胞肺癌的抗癌药物 Repurposing the anti-dementia drug memantine, (a dualalpha7-nAChR NMDAR antagonist) as an anti-cancer agent in human squamous cell lung cancer Javan Christian, Sarah L. Miles, Kritsa L. Denning, Kushal J. Modi, Reagan S. Light, Piyali Dasgupta, Yi Charlie Chen
-
- 4465 4465 咪康唑通过p53介导的通路诱导前列腺癌细胞的细胞周期停滞和凋亡：一种药物重定位策略 Miconazole induces cell cycle arrest and apoptosis in prostate cancer cells via a p53-mediated pathway: A Drug repurposing strategy Eswara Naga Hanuma Kumar Ghali, Lindsey Shim, Rahul Tiwari, Rajasekhar Baru, Anupam Dhasmana, Chang Ryan Jisoo, Sung Yun Jung, Vivek Kumar Kashyap, Neeraj Chauhan, Subhash C. Chauhan, Murali M. Yallapu
- 4466 4466 临床级CK2抑制剂CX-4945在临床前急性髓系白血病模型中协同增强venetoclax介导的抗白血病活性 Clinical-grade CK2 inhibitor CX-4945 synergistically enhances venetoclax-mediated antileukemic activity in preclinical acute myeloid leukemia models Upendarrao Golla, Muhammad Danial, Rajesh Rajaiah, Marudhu Pandiyan Shanmugam, Koby Duke, Katherine Mercer, Yi Qiu, Sinisa Dovat, Yasin Uzun, Hong Zheng, Suming Huang, Chandrika G. Behura
-
-
-
- 4470 4470 NAMPT抑制剂联合嘧啶类似物抗代谢药氟尿苷和5-FU损害横纹肌肉瘤的增殖和存活 Combination of NAMPT inhibitors plus pyrimidine analog antimetabolites floxuridine and 5-FU impair rhabdomyosarcoma proliferation and survival Jamie Gudyka, Choh Yeung, Senna Munnikhuysen, Christina M. Robinson, Amy James, Xiaohu Zhang, David Holland, Michele Ceribelli, Simone Difilippantonio, Craig J. Thomas, Christine M. Heske
- 4471 4471 负载2-DG和二甲双胍的电纺支架的协同代谢抑制破坏胶质母细胞瘤的氧化还原平衡和糖酵解产出 Synergistic metabolic inhibition with 2-DG and metformin loaded electrospun scaffolds disrupts glioblastoma redox balance and glycolytic output Bryce William Jewett
- 4472 4472 甲羟孕酮乙酸酯(MPA)与WEE1或ATR抑制剂联用增强雌激素受体阳性子宫内膜癌细胞的抗肿瘤活性 Combination of medroxyprogesterone acetate (MPA) and a WEE1 or ATR inhibitor enhances anti-tumor activity of estrogen receptor-positive endometrial cancer cells Yuki Takemoto, Yasuto Kinose, Li Han, Mai Koizumi, Yan Wang, Kanako Kasuya, Aasa Shimizu, Erika Nakatsuka, Mahiru Kawano, Kenjiro Sawada, Michiko Kodama
-
- 4474 4474 大麻二酚通过激活p53-mTOR-TFEB溶酶体死亡程序增强依托泊苷在非小细胞肺癌中的疗效 Cannabidiol enhances etoposide efficacy in non-small cell lung cancer by engaging a p53-mTOR-TFEB lysosomal death program Youngsic Jeon, Hyukjoon Kwon, Young Nyun Park, Taejung Kim, Young-Joo Kim
-
- 4476 4476 在分子学定义的腹膜转移性结直肠癌(pmCRC)亚组中重新利用PARP抑制剂：患者来源异种移植(PDX)模型的临床前分析 Repurposing PARP inhibitors in molecularly defined subgroups of peritoneal metastatic colorectal cancer (pmCRC): Preclinical analysis of patient-derived xenograft (PDX) models Mathias Dahlmann, Beate Rau, Safak Gül-Klein, Bernadette Brzezicha, Marlen Keil, Antje Wengner, Jens Hoffmann, Sebastian Stintzing, Ulrike S. Stein, Wolfgang Walther, Loredana Vecchione
-
